Core Insights - Nxera Pharma's partner Tempero Bio has initiated a Phase 2 trial for TMP-301, targeting alcohol use disorder, with the trial registered under Clinical Trial ID: NCT06648655 [1] - Tempero Bio has closed a $70 million financing round to support the advancement of TMP-301 through the Phase 2 trial and to prepare for a second Phase 2 trial for cocaine use disorder [1][2] - The Phase 2 study will evaluate the safety, tolerability, and efficacy of TMP-301 compared to a placebo in patients with alcohol use disorder [2] Company Developments - Matt Barnes, EVP and President of Nxera Pharma UK, expressed excitement about the advancement of TMP-301, highlighting the strength of the NxWave™ discovery platform [3] - Nxera Pharma has a pipeline of over 30 active programs, focusing on unmet medical needs across various therapeutic areas, leveraging its GPCR-targeted structure-based drug discovery platform [8] - Nxera Pharma has a strategic equity stake in Tempero Bio and is eligible for future milestone payments and tiered royalties from product sales [4] Financial Aspects - The $70 million financing will be utilized for advancing TMP-301 through clinical trials and conducting preclinical studies for additional indications [1] - There are no milestone payments due from Tempero Bio to Nxera associated with the start of the Phase 2 trial [5]
Nxera Pharma's Partner Tempero Bio Initiates Phase 2 Trial with TMP-301 for Alcohol Use Disorder